Edgewell Closes Feminine Care Sale, Maintains FY26 Guidance After a Modest Q1 Beat

Overview

• The feminine care business sale to Essity has closed and is now reported as discontinued operations, with prior periods recast for comparability.
• Q1 fiscal 2026 results on continuing operations modestly topped internal expectations, with organic sales roughly flat (down about 0.5%) and adjusted EBITDA around $25 million.
• Earlier-than-expected North America sun-care shipments drove the quarter, while wet shave softened and international markets were weaker as anticipated.
• Full-year outlook is unchanged: organic net sales down 1% to up 2%, adjusted EPS of $1.70–$2.10 including an estimated $0.44 EPS headwind from the divestiture, and adjusted EBITDA of $245–$265 million.
• Management emphasized portfolio focus on shave, sun, skincare and grooming, signaled no near-term M&A, and left open opportunistic share repurchases.